Quotient Blog Technical Feasibility Established for MosaiQ CMV and Syphilis Disease Screening Assays

<p><strong>JERSEY, Channel Islands, June 23, 2014&#160;</strong>Quotient Limited ("Quotient"; NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that results generated using the MosaiQ&#8482; methodology demonstrated a high degree of concordance to predicate technologies screening blood for Cytomegalovirus (CMV) and Syphilis. The feasibility study was conducted in collaboration with Future Diagnostics Solutions B.V. (Wijchen, The Netherlands) and examined a total of 274 positive and negative samples.</p>